SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series March listing by industry category 03/10

20100076200 - Purification of olmesartan medoxomil: The present invention provides a process for purifying olmesartan medoxomil.... Agent: Kenyon & Kenyon LLP

20100076201 - Carbazole derivative and method for producing the same: e

20100076202 - Method for producing pyrrolidine derivative:

20100076203 - Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation: wherein R1 is an amino group protected with a group removed by hydrogenolysis or a tert-butoxycarbonylamino group and R2 is an ethyl group optionally substituted with one or two methyl group(s) at α-position, provided that R2 is not a tert-butyl group when R1 is a tert-butoxycarbonylamino group; with alkali metal... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100076204 - Process for the preparation of levetiracetam: The present invention relates to a process for the preparation of levetiracetam and, more particularly, to an improved process for the preparation of levetiracetam characterized by a crystallization-induced dynamic resolution of a diastereoisomeric mixture of an (±)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide derivative.... Agent: Lucas & Mercanti, LLP

20100069643 - Convergent process for the synthesis of taxane derivatives: The application provides a process for the preparation of taxane derivatives and intermediates useful in such processes.... Agent: Morgan, Lewis & Bockius LLP

20100069644 - Method of regio-selective synthesis of tri-substituted-1, 2, 3-triazoles: The embodiments provide for region-selective synthesis of tri-substituted 1,2,3-traizoles. A first embodiment provides for the selective N-2 alkylation of a 4,5-disubstituted 1,2,3-triazole. A second embodiment provides for the selective acetylation of a 4,5-disubstituted 1,2,3-triazole. A third embodiment provides for the selective arylation of a 4,5-disubstituted 1,2,3-triazole.... Agent: West Virginia University Research Corporation

20100069645 - 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and methyl ester: A series of S-triazolyl α-mercaptoacetanilides having general structure (I) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100069646 - Process for preparing difluoromethylpyrazolyl carboxylates: s

20100069647 - Carbazole derivative, light-emitting element material, light-emitting element, and light-emitting device: An object is to provide a carbazole derivative which has a wide band gap and with which excellent blue color purity is obtained. In addition, another object is to provide highly reliable light-emitting elements, light-emitting devices, lighting devices, and electronic devices in which the carbazole derivative is used. Carbazole derivatives... Agent: Cook Alex Ltd

20100069648 - Adamantane-dipyrromethane derivatives, method of preparation and applications in anion sensing: Aamantane dipyrromethane derivatives are obtained by reacting adamantane carbonyl derivatives with pyrrole or pyrrole derivative, in the presence of acid. Adamantane-dipyrromethanes are used to bind anions of the group consisting of: F—, Cl—, Br—, acetate, HSO4— NO3—, and H2PO4—, and particularly F—.... Agent: St. Onge Steward Johnston & Reens, LLC

20100063295 - Primary explosives: The present invention provides a compound of the formula (Cat)+z[M++(5-nitro-1H-tetrazolato-N2)−x(H2O)y] where x is 3 or 4, y is 2 or 3, x+y is 6, z is 1 or 2, and M++ is selected from the group consisting of iron, cobalt, nickel, copper, zinc, chromium, and manganese, and (Cat)+ is selected... Agent: Los Alamos National Security, LLC

20100063296 - Composition for treating infectious diseases caused by helicobacter: The invention relates to a compound of general formula (I) for use in a pharmaceutical composition for treating infectious diseases caused by Helicobacter pylori. R1 and R2 are O, S or N, and can be identical or different; R3 is O or S; R4 is H or a C1-C6 alkyl... Agent: Ip Patent Docketing K&l Gates LLP

20100063297 - Processes for the preparation of 1,2,4-oxadiazole benzoic acids: Provided herein are processes for the preparation of compounds useful for the treatment, prevention or management of diseases associated with a nonsense mutation. More specifically, provided herein are processes for the synthesis of 1,2,4-oxadiazoles. In particular, provided herein are processes useful for the preparation of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid.... Agent: Jones Day

20100063298 - 11c-labeled benzophenone/benzoxazole analogues as an inflammation imaging agent: A method of preparing novel [11C]-labeled benzophenone/bezoxazole analogues is provided. The present invention also provides novel [11C]-labeled benzophenone/bezoxazole analogues prepared from the GMP synthesis method. Kit claims for preparing novel [11C]-labeled benzophenone/bezoxazole analogues and a method of use thereof are also provided.... Agent: Ge Healthcare, Inc.

20100063299 - Process for preparing irbesartan: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Irbesartan, or a pharmaceutically acceptable salt thereof, in high yield and purity.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100063300 - Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds: s

20100063301 - Synthesis of thrombopoietin activity modulating compounds: Disclosed herein are various methods for synthesizing compounds that modulate thrombopoietin activity. Also disclosed are intermediates useful for the preparation of these compounds.... Agent: Knobbe Martens Olson & Bear LLP

20100056797 - Process for the preparation of irbesartan: The present invention relates to an improved process for the preparation of 2-n-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]-1,3-diazaspiro[4.4]non-1-en-4-one (Irbesartan)... Agent: Jay R Akhave

20100056798 - Substituted thien-3-yl-sulphonylamino(thio)carbonyl-triazolin(ethi)ones: e

20100056799 - Stable isotope-labeled aromatic amino acids, method for incorporating the same in target protein and method for nmr-structural analysis of proteins: The present invention herein provides, for instance, a stable isotope-labeled phenylalanine wherein a carbon atom of the phenyl group linked to an amino acid residue is 13C, 2 to 4 carbon atoms of the remaining 5 carbon atoms constituting the phenyl group are 12C atoms to which deuterium atoms are... Agent: Hoffmann & Baron, LLP

20100056800 - Method of synthesizing 1h-indazole compounds: A method is provided for synthesizing 1H-indazole compounds in which aromatic carbonyl compounds are reacted with a nitrogen source to form oximes which are then converted to 1H-indazoles.... Agent: Dinsmore & Shohl LLP

20100056801 - Compounds and compositions containing silicon and/or other heteroatoms and/or metals and methods of making and using them: The present invention relates to compounds, intermediates, compositions, and methods of making compounds and intermediates related to the compounds of Formula (I) and/or Formula (II) and/or Formula (III) and/or Formula (IV) and/or Formula (VI) and/or Formula (VII) as disclosed herein wherein the various substituents are as defined in the written... Agent: Kilpatrick Stockton LLP

20100056802 - Amorphous form of an l-arginine salt of perindopril and processes for preparation thereof: In illustrative embodiments, there is provided an amorphous form of L-arginine salt of perindopril which may be particularly suitable for pharmaceutical applications, and processes for preparing said form.... Agent: Apotex, Inc.

20100056803 - Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium... Agent: Apotex, Inc.

20100056804 - Compound containing carboxylate ester and n2s2 ligand bi-functional groups and manufacturing method thereof: A compound containing carboxylate ester and N2S2 ligand bi-functional groups and a manufacturing method thereof are disclosed. The S in the N2S2 ligand of the compound containing carboxylate ester and N2S2 ligand bi-functional groups includes a protective group so as to avoid to be oxidized and easy storage. In a... Agent: Sinorica, LLC

20100056805 - Process for producing 3,4-disubstituted pyrrolidine derivative and production intermediate thereof: Highly stereoselective asymmetric hydrogenation of 1-protected-4-alkoxycarbonyl-3-oxopyrrolidine, followed by ester hydrolysis, followed by amidation with cyclopropylamine gives crude crystals. The crude crystals are purified by recrystallization to give a novel compound (3R,4S)-1-protected-3-cyclopropylcarbamoyl-4-hydroxypyrrolidine or an enantiomer thereof at high optical purity. The use of these intermediates enables industrial production of high-quality products... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056806 - C-h bond amination and olefin aziridination with beta-diketiminato copper catalysts: One aspect of the present invention relates to a method for the transition metal (e.g., Cu(I)) mediated amidation of C—H bonds using electron-rich aliphatic azides. In certain embodiments, the methods are useful for the C—H insertion of nitrenes generated and stabilized by a β-diketiminato metal catalyst. In certain embodiments, said... Agent: Foley Hoag, LLP Patent Group, World Trade Center West